Medical Weight Loss Programs (Telehealth)

Medical weight loss programs via telehealth platforms -- Hims and Hers, WeightWatchers Clinic (WW Med+), Found Health, Noom Med, and Ro -- represent a structural innovation in how obesity treatment reaches patients rather than a distinct pharmacological intervention. They combine clinician-prescribed medications (primarily GLP-1s), regular virtual medical oversight, and behavioral coaching in subscription models. In 2026, these programs restructured after FDA enforcement against compounded semaglutide accelerated. Most platforms transitioned to brand-name medications with manufacturer self-pay programs, improving safety while increasing medication costs. Hims and Hers Weight Loss: membership $39/month first month, $149/month ongoing, with bundled virtual clinician consultations and GLP-1 access (~$199/month above membership for brand-name injectables). WeightWatchers Clinic (WW Med+): introductory $199/month (through March 2026), standard $349/month integrating WW behavioral program with GLP-1 access. Found Health: compounded semaglutide at ~$189/month with transition to brand-name underway. A 2024 JAMA Network Open analysis found telehealth patients on GLP-1s achieved weight loss within 1-2% of in-person cohorts at 6 months. Best suited for patients with BMI 27+ with comorbidity or BMI 30+ who lack access to obesity medicine specialists, prefer virtual care, or benefit from bundled behavioral support alongside pharmacotherapy.